Denali Therapeutics (DNLI) Revenue (2018 - 2023)

Denali Therapeutics (DNLI) has 6 years of Revenue data on file, last reported at $1.3 million in Q3 2023.

• Revenue for Q3 2023 came in at $1.3 million, up 588.59% year-over-year; the trailing twelve-month figure through Jun 2024 was $1.3 million (down 99.63% YoY), and the FY2023 annual result was $330.5 million, up 9627.22% from the prior year.
• Revenue slipped to $1.3 million in Q3 2023 per DNLI's latest filing, from $294.1 million in the prior quarter.
• Over five years, Revenue peaked at $316.8 million in Q4 2020 and troughed at $1000.0 in Q1 2021.
• A 5-year average of $42.1 million and a median of $5.3 million in 2021 frame the typical range for Revenue.
• The sharpest annual moves came in 2020 and 2022: Revenue plunged 98.76% in 2020, then jumped 4214000.0% in 2022.
• A 5-year view of Revenue shows it stood at $4.7 million in 2019, then jumped by 6681.14% to $316.8 million in 2020, then plunged by 96.05% to $12.5 million in 2021, then slipped by 20.09% to $10.0 million in 2022, then slumped by 87.33% to $1.3 million in 2023.
• Business Quant data shows DNLI's Revenue at $1.3 million in Q3 2023, $294.1 million in Q2 2023, and $35.1 million in Q1 2023.